Pliant to flesh out fibrosis pipeline after NASH deal with Novartis

Pliant’s deal to out-license its NASH candidate to Novartis for $80 million will allow the fibrosis company to fund development of its lead candidate, as well as advance its preclinical pipeline.

Novartis AG (NYSE:NVS; SIX:NOVN) will receive an exclusive, worldwide

Read the full 390 word article

How to gain access

Continue reading with a
two-week free trial.